Usefulness of Medication Guidance Sheets for Patients With Non-Hodgkin's Lymphoma Receiving ESHAP±R Therapy

Mayako Uchida; Saeko Murata; Hanae Morikawa; Hiroko Yonemitsu; Shigeru Ishida; Kimitaka Suetsugu; Toshikazu Tsuji; Hiroyuki Watanabe; Takehiro Kawashiri; Koji Kato; Keiko Hosohata; Toshihiro Miyamoto; Nobuaki Egashira; Tsutomu Nakamura; Koichi Akashi; Ichiro Ieiri

doi:10.21873/anticanres.15686

Usefulness of Medication Guidance Sheets for Patients With Non-Hodgkin's Lymphoma Receiving ESHAP±R Therapy

Mayako Uchida, Saeko Murata, Hanae Morikawa, Hiroko Yonemitsu, Shigeru Ishida, Kimitaka Suetsugu, Toshikazu Tsuji, Hiroyuki Watanabe, Takehiro Kawashiri, Koji Kato, Keiko Hosohata, Toshihiro Miyamoto, Nobuaki Egashira, Tsutomu Nakamura, Koichi Akashi, Ichiro Ieiri

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND/AIM: The occurrence of chemotherapy-related serious adverse events (AEs) is associated with a poor prognosis of hematopoietic malignancies. We have developed a medication guidance sheet (MGS) for monitoring AEs occurring when combining chemotherapy with etoposide, methylprednisolone, cisplatin, cytarabine, and rituximab (ESHAP±R). In this study, the usefulness of MGS was investigated in non-Hodgkin's lymphoma patients.

PATIENTS AND METHODS: The MGS was used to monitor AEs in 48 adult patients receiving ESHAP±R. The prediction accuracy of the MGS was estimated before and after modification based on practical data.

RESULTS: A total of 246 AEs developed, all of which were predicted by the MGS. Among them, 149 events (61%) occurred during the same period as those predicted by the MGS. After modification of MGS for the onset and duration of AEs, the accuracy increased to 84%.

CONCLUSION: The accuracy of the original MGS for ESHAP±R was insufficient but greatly improved after the AEs duration modification.

Original language	English
Pages (from-to)	2053-2060
Number of pages	8
Journal	Anticancer research
Volume	42
Issue number	4
DOIs	https://doi.org/10.21873/anticanres.15686
Publication status	Published - Apr 2022

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/anticanres.15686

Cite this

Uchida, M., Murata, S., Morikawa, H., Yonemitsu, H., Ishida, S., Suetsugu, K., Tsuji, T., Watanabe, H., Kawashiri, T., Kato, K., Hosohata, K., Miyamoto, T., Egashira, N., Nakamura, T., Akashi, K., & Ieiri, I. (2022). Usefulness of Medication Guidance Sheets for Patients With Non-Hodgkin's Lymphoma Receiving ESHAP±R Therapy. Anticancer research, 42(4), 2053-2060. https://doi.org/10.21873/anticanres.15686

Uchida, M, Murata, S, Morikawa, H, Yonemitsu, H, Ishida, S, Suetsugu, K, Tsuji, T, Watanabe, H, Kawashiri, T , Kato, K, Hosohata, K, Miyamoto, T, Egashira, N, Nakamura, T, Akashi, K & Ieiri, I 2022, 'Usefulness of Medication Guidance Sheets for Patients With Non-Hodgkin's Lymphoma Receiving ESHAP±R Therapy', Anticancer research, vol. 42, no. 4, pp. 2053-2060. https://doi.org/10.21873/anticanres.15686

@article{af5d334fad734d449a97f64974390069,

title = "Usefulness of Medication Guidance Sheets for Patients With Non-Hodgkin's Lymphoma Receiving ESHAP±R Therapy",

abstract = "BACKGROUND/AIM: The occurrence of chemotherapy-related serious adverse events (AEs) is associated with a poor prognosis of hematopoietic malignancies. We have developed a medication guidance sheet (MGS) for monitoring AEs occurring when combining chemotherapy with etoposide, methylprednisolone, cisplatin, cytarabine, and rituximab (ESHAP±R). In this study, the usefulness of MGS was investigated in non-Hodgkin's lymphoma patients.PATIENTS AND METHODS: The MGS was used to monitor AEs in 48 adult patients receiving ESHAP±R. The prediction accuracy of the MGS was estimated before and after modification based on practical data.RESULTS: A total of 246 AEs developed, all of which were predicted by the MGS. Among them, 149 events (61%) occurred during the same period as those predicted by the MGS. After modification of MGS for the onset and duration of AEs, the accuracy increased to 84%.CONCLUSION: The accuracy of the original MGS for ESHAP±R was insufficient but greatly improved after the AEs duration modification.",

author = "Mayako Uchida and Saeko Murata and Hanae Morikawa and Hiroko Yonemitsu and Shigeru Ishida and Kimitaka Suetsugu and Toshikazu Tsuji and Hiroyuki Watanabe and Takehiro Kawashiri and Koji Kato and Keiko Hosohata and Toshihiro Miyamoto and Nobuaki Egashira and Tsutomu Nakamura and Koichi Akashi and Ichiro Ieiri",

year = "2022",

month = apr,

doi = "10.21873/anticanres.15686",

language = "English",

volume = "42",

pages = "2053--2060",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "4",

}

TY - JOUR

T1 - Usefulness of Medication Guidance Sheets for Patients With Non-Hodgkin's Lymphoma Receiving ESHAP±R Therapy

AU - Uchida, Mayako

AU - Murata, Saeko

AU - Morikawa, Hanae

AU - Yonemitsu, Hiroko

AU - Ishida, Shigeru

AU - Suetsugu, Kimitaka

AU - Tsuji, Toshikazu

AU - Watanabe, Hiroyuki

AU - Kawashiri, Takehiro

AU - Kato, Koji

AU - Hosohata, Keiko

AU - Miyamoto, Toshihiro

AU - Egashira, Nobuaki

AU - Nakamura, Tsutomu

AU - Akashi, Koichi

AU - Ieiri, Ichiro

PY - 2022/4

Y1 - 2022/4

N2 - BACKGROUND/AIM: The occurrence of chemotherapy-related serious adverse events (AEs) is associated with a poor prognosis of hematopoietic malignancies. We have developed a medication guidance sheet (MGS) for monitoring AEs occurring when combining chemotherapy with etoposide, methylprednisolone, cisplatin, cytarabine, and rituximab (ESHAP±R). In this study, the usefulness of MGS was investigated in non-Hodgkin's lymphoma patients.PATIENTS AND METHODS: The MGS was used to monitor AEs in 48 adult patients receiving ESHAP±R. The prediction accuracy of the MGS was estimated before and after modification based on practical data.RESULTS: A total of 246 AEs developed, all of which were predicted by the MGS. Among them, 149 events (61%) occurred during the same period as those predicted by the MGS. After modification of MGS for the onset and duration of AEs, the accuracy increased to 84%.CONCLUSION: The accuracy of the original MGS for ESHAP±R was insufficient but greatly improved after the AEs duration modification.

AB - BACKGROUND/AIM: The occurrence of chemotherapy-related serious adverse events (AEs) is associated with a poor prognosis of hematopoietic malignancies. We have developed a medication guidance sheet (MGS) for monitoring AEs occurring when combining chemotherapy with etoposide, methylprednisolone, cisplatin, cytarabine, and rituximab (ESHAP±R). In this study, the usefulness of MGS was investigated in non-Hodgkin's lymphoma patients.PATIENTS AND METHODS: The MGS was used to monitor AEs in 48 adult patients receiving ESHAP±R. The prediction accuracy of the MGS was estimated before and after modification based on practical data.RESULTS: A total of 246 AEs developed, all of which were predicted by the MGS. Among them, 149 events (61%) occurred during the same period as those predicted by the MGS. After modification of MGS for the onset and duration of AEs, the accuracy increased to 84%.CONCLUSION: The accuracy of the original MGS for ESHAP±R was insufficient but greatly improved after the AEs duration modification.

UR - http://www.scopus.com/inward/record.url?scp=85127233729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127233729&partnerID=8YFLogxK

U2 - 10.21873/anticanres.15686

DO - 10.21873/anticanres.15686

M3 - Article

C2 - 35347028

VL - 42

SP - 2053

EP - 2060

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -

Usefulness of Medication Guidance Sheets for Patients With Non-Hodgkin's Lymphoma Receiving ESHAP±R Therapy

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this